Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Administered circulating microparticles derived from lung cancer patients markedly improved angiogenesis, blood flow and ischemic recovery in rat critical limb ischemia

Figure 3

Upper Panel) Ratio of ischemic/ normal blood flow (INBF) by Laser Doppler scan on day 0 prior to procedure and on days 2, 7 and 14 after critical limb ischemia (CLI) procedure (n =  10). A) Showing normal blood flow at baseline, days 2, 7 and 14 of both hind limbs among five groups. B) Analytical results of ratios of ischemic (left limb)/normal (right limb) blood flow (INBF) Laser Doppler at day 0 prior to CLI procedure) and days 2, 7 and 14 after CLI procedure. By day 2, * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001; By day 7, * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001; By day 14, * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. Lower Panel) Protein expressions of angiogenesis factors of ischemic quadriceps on day 14 following critical limb ischemia (CLI) procedure (n = 8). C) Protein expression of vascular endothelial growth factor (VEGF); D) Protein expression of stromal cell-derived factor (SDF)-1α; E) Protein expression of CXCR4; F) Protein expression of angiopoietin 1 (ANGPT 1); * vs. other groups with different symbols (*, †, ‡, §), p < 0.001. G) Protein expression of hepatocyte growth factor (HGF); I) Protein expression of CD31; Protein expression of endothelial nitric oxide synthase (eNOS); * vs. other groups with different symbols (*, †, ‡, §), p < 0.005. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n = 7). Symbols (*, †, ‡, §) indicate significance (at 0.05 level). SC = sham control; CLI = critical limb ischemia; Lc-MPs = lung-cancer patient-derived microparticles; Hs-MPs = Healthy subject-derived microparticles.

Back to article page